Answers are grounded in this paper and cite their sources.
Clinical evaluation reveals extended treatment intervals and anatomical gains with faricimab in aflibercept-resistant diabetic macular edema, suggesting an effective alternative therapy.
A longer treatment interval and improved functional and anatomical outcomes at 12 months may be attained in a clinically significant minority of aflibercept-resistant DME patients after changing to IVF when a TAE protocol is employed. Specialists may consider IVF whenever resistance to IVA is experienced in this patient population.
No takes yet. Share an insight, caveat, or question.
Ryan B. Rush (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: